Wednesday, August 4, 2021

Abivax’s ABX464 shows ‘impressive’ efficacy in severe ulcerative colitis patients

French biotech company Abivax has revealed positive topline results from a Phase IIb study of its investigational oral drug candidate ABX464 in ulcerative colitis (UC) patients.

In the study, 254 patients with moderate-to-severe UC received treatment with ABX464, with topline data showing significant clinical efficacy in the overall population on both primary and key secondary endpoints.

Of these patients, 50% had inadequate response, loss of response or intolerance to tumour necrosis factor alpha (TNF-α) inhibitors, Takeda Entyvio (vedolizumab), other biologics and/or JAK inhibitor treatments, while the other half were refractory to conventional treatments.

Preliminary results from the open label maintenance study in the first 51 patients after 48 weeks of treatment with ABX464 demonstrated 53% in clinical remission and 59% with endoscopic improvement.

The treatment was also well tolerated and demonstrated a good safety profile, with an overall drop-out rate of patients in the study being 9%.

“The phase 2b results demonstrate the potential of ABX464 to become a gamechanger for the treatment of ulcerative colitis patients in need of new therapeutic management options,” said Hartmut Ehrlich, chief executive officer of Abivax.

“Interestingly, the lowest dose of 25mg was effective across the entire study population, including patients refractory to biologics and JAK inhibitors, with a safety profile that is very similar to the placebo group.

“Based on these data, we are now moving forward as quickly as possible with our Phase III plan in ulcerative colitis as well as Phase IIb/III in Crohn’s disease to bring ABX464 to the many patients suffering from inflammatory bowel disease,” he added.

Abivax is planning to submit the Phase IIb study results to a peer-reviewed journal, as well as at upcoming ‘major scientific conferences’.

Source link

Stay Connected


Latest Articles

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...